Quarterly report pursuant to Section 13 or 15(d)

Background (Details)

v3.23.3
Background (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
May 24, 2022
USD ($)
$ / shares
shares
Sep. 30, 2023
USD ($)
$ / shares
shares
Oct. 01, 2022
USD ($)
Sep. 30, 2023
USD ($)
segment
$ / shares
shares
Oct. 01, 2022
USD ($)
Jul. 01, 2023
USD ($)
Apr. 01, 2023
USD ($)
Dec. 31, 2022
USD ($)
$ / shares
shares
Jul. 02, 2022
USD ($)
Apr. 02, 2022
USD ($)
Jan. 01, 2022
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Number of operating segments | segment       3              
Potential market exclusivity period       7 years              
Common stock, issued shares (in shares) | shares   4,957,647   4,957,647       2,827,410      
Common Stock, par value (in usd per share) | $ / shares   $ 0.001   $ 0.001       $ 0.001      
Net loss   $ 214 $ 1,981 $ (9,993) $ (8,104)            
Current assets   517   517       $ 9,173      
Current liabilities   2,504   2,504       23,938      
Working capital       1,900              
Stockholders' equity   $ 14,498 $ (575) 14,498 $ (575) $ 13,688 $ 13,560 $ 2,307 $ 1,406 $ (7,510) $ (8,676)
Biotechnology                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Net loss       754              
Cash used in operations from continuing operations       $ 500              
SPYR Technologies Inc. | Asset Purchase Agreement                      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                      
Agreed prepayment amount $ 13,500                    
Common stock, issued shares (in shares) | shares 30,000,000                    
Common Stock, par value (in usd per share) | $ / shares $ 0.03                    
Term of notes receivable (years) 5 years                    
Note receivable face amount $ 12,600                    
Note receivable interest rate (percent) 8.00%